An inspiring play about Parkinson’s and Parkour is coming to a theatre near you
Author: Geoffrey ChangPublished: 8 September 2016
Prep: Cook: Serves:
A new thought-provoking play that explores the friendship between a free-running teenager and a woman with early-onset Parkinson’s is going on a nationwide tour
After three sell-out shows in cities across the UK and rave reviews, a new Parkinson’s play called Kinetics is taking to the road for a run of 13 performances throughout September and October.
Based on a true story, the inspiring theatre piece explores the unlikely friendship between a teenage boy who is devoted to free running (Parkour) – the extreme sport that involves navigating obstacles without equipment – and a middle-aged woman with early-onset Parkinson’s disease.
But what can they possibly have in common? Despite living completely opposing lives, a chance encounter leads the two protagonists to realise the answer: they share the desire to move.
Featuring projected imagery and electrifying live Parkour, the show raises awareness of Parkinson’s with wit, while challenging perceptions and giving a realistic insight into the daily struggles that come with living with the condition.
Written by actor and drama teacher, Sue Wylie, the play recounts her personal experience of living with Parkinson’s. Sue, who performs the lead role, explains: “Five years ago shortly after my 50th birthday I was diagnosed with Parkinson’s. After the initial shock I knew I wanted to write about it. I was teaching drama at the time and discovered that a bright but rebellious 16-year-old student in my tutor group was free running on the school roof.
“I was intrigued by the risks he took in his addiction to this extreme sport. How interesting to contrast that with a middle-aged woman whose world of movement is slowly being eroded. What if their paths should accidentally cross and a friendship form? I knew there was a story in there and so Kinetics was born.”
Sue Wylie (left) playing lead character Rose
Through the juxtaposition of the characters the sharp script, full of emotion and humour, unexpectedly draws parallels between two lives that couldn’t seem more opposite. The two learn more important life lessons from one another than they ever could have imagined.
Following the initial success of sold out shows last year, Kinetics received funding from the Arts Council, allowing them to organise the upcoming Autumn 2016 tour. Parkinson’s UK have officially endorsed the play with CEO Steve Ford saying: “Sue’s play offers an inspiring story to which we can all relate.”
A new online hub provides essential DBS info, resources and tools
6 days ago
Can Covid-19 increase the risk of developing Parkinson’s?
Parkinson’s could be caused or modulated by infections like Covid-19, a new study suggests – though more evidence is needed to draw a definitive conclusion. As part of the study, researchers from the Federal University of São Paulo, Brazil, drew on previous findings to support their hypothesis. For example, studies in mice have found that infection with some strains of influenza could cause neural changes similar to those in Parkinson’s. Furthermore, people born during or around the 1918 influenza pandemic were over twice as likely to develop Parkinson’s than those born in the decades before or after. Patrik Brundin, co-editor-in-chief of the Journal of Parkinson’s Disease, said that while it’s “too early to know what the long-term consequences of Covid-19 will be on the brain, the clinical psychiatry and neurology research communities definitely need to be vigilant in monitoring how those who recover from moderate and severe Covid-19 fare in…
New Parkinson’s trial platform could “dramatically speed up the search for a cure”
Scientists have proposed the use of a multi-arm, multi-stage trial platform (MAMS) to assess different potential treatments for Parkinson’s and help progress the search for a cure. This would depart from conventional clinical procedures, allowing several potential treatments to be assessed simultaneously. In a continuous process, each treatment ‘arm’ is evaluated and unsuccessful ‘arms’ of the trial are dropped, enabling a far more cost and time efficient system. Currently, MAMS are used to evaluate treatments for certain types of cancer – and work is underway to develop MAMS for other neurodegenerative conditions. Camille Buchholz Carroll, associate professor at the University of Plymouth, UK, and study author, said that MAMS trials could “dramatically speed up the search for a cure”. She said: “We have the opportunity to learn from the experience in these other conditions and design a new trial that will work for people with Parkinson’s.”
Can higher levels of caffeine and uric acid prevent Parkinson’s?
Higher levels of caffeine and uric acid (a natural waste product) may reduce the risk of Parkinson’s, a new study by researchers in the US has found. As part of the study – published in ‘Journal of Parkinson’s Disease’ – researchers investigated the urate levels and caffeine intake of 566 participants in the Harvard Biomarkers Study, 369 of which had Parkinson’s. The results showed that caffeine intake and uric acid levels were lower in people with Parkinson’s compared to the healthy controls. While the study provides evidence of the link between Parkinson’s and higher uric acid and caffeine levels, the researchers caution that attempts to raise these levels cannot be recommended. Dr Rachit Bakshi, lead investigator of the study, said: “Identifying factors that are linked to lower likelihood of PD, such as caffeine consumption, offer a unique opportunity to understand the disease, and if the link were causal, then possibly…